News
News
March 2022
Impressive long-term cancer control data from the largest and longest study of focal HIFU treatment
Encouraging results of long-term cancer control data from the longest study of focal HIFU treatment was recently publishes in European Urology.
Read more
February 2022
Promising long-term efficacy of HIVEC therapy using Combat BRS for BCG-unresponsive NMIBC patients
Impressive results regarding long-term efficacy of hyperthermic intravesical chemotherapy (HIVEC) using Combat BRS for BCG-unresponsive, non-muscle invasive bladder cancer (NMIBC) patients was recently published in Urologic Oncology.
Read more
December 2021
Many thanks and Christmas greetings to all our customers and partners
As 2021 comes to an end, this is our time to say thank you.
Read more
September 2021
Film Kavita & Teresa inspires people to think about true values in life
The film by Swiss-Indian filmmaker Kamal Musale is a contemporary drama and an epic biopic about Mother Teresa, which inspires to look at one's own values and to live compassion, respect and love in one's personal environment. A captivating movie that we at innoMedicus encourage you to watch.
Read more
May 2021
World’s largest propensity matched comparison of salvage RARP matched to primary RARP
Encouraging results of the world’s largest propensity matched comparison of salvage robot-assisted radical prostatectomy (RARP) after focal and whole gland nonsurgical primary therapy from the UK group has been published in the European Urology Open Science.
Read more
March 2021
Intravesical hyperthermia with high-dose mitomycin-C shows promise as BCG alternative for NMIBC
Treatment for high-risk non–muscle-invasive bladder cancer (NMIBC) with hyperthermic intravesical chemotherapy (HIVEC) using high-dose mitomycin-C (MMC) is safe, well tolerated, and appears efficacious after short-term follow-up, according to a report from Duke University urologists, which has been published in Urologic Oncology.
Read more
February 2021
Non-Contrast MRI may have favourable characteristics as a screening test of prostate cancer
The first study to compare bi-parametric MRI, ultrasound and PSA as a screening test for prostate cancer has been recently published in JAMA Oncology.
Read more
January 2021
The first U.S. study on focal HIFU therapy has been published since FDA clearance
The publication at The Journal of Urology entitled “High Intensity Focused Ultrasound Hemigland Ablation for Prostate Cancer: Initial Outcomes of a United States Series” details the study of 100 men with biopsy-confirmed prostate cancer, 72% of which were classified with intermediate or high-risk disease.
Read more
December 2020
Many thanks and Christmas greetings to all our customers and partners
This year was a very challenging year for all of us. All the more we would like to thank you for your loyalty and for believing in us.
Read more
October 2020
Focal ablative therapy compared to radical prostatectomy provides equivalent oncological outcomes over 8 years
After the tremendous success of the FOCAL2019 in Miami, the annual conference on the Frontiers in Oncologic Prostate Care and Ablative Local Therapy FOCAL2020 took place virtually where a lot of participants from the world over attended this cutting-edge meeting despite Covid-19 restrictions.
Read more
September 2020
What Type of Prostate Cancer is Systematically overlooked by mp-MRI?
mpMRI has dramatically changed how urologists diagnose and monitor prostate cancer, as it not only allows lesions to be targeted in biopsies but also helps in deciding which patients to biopsy.
Read more
August 2020
Promising results with Combat HIVEC in high risk non-muscle invasive bladder cancer patients
Promising preliminary results from HIVEC-HR randomized trial with 24 months of median follow-up, presented by a group of urologists from the Hospital Universitario 12 de Octubre, Madrid, peaked great interest at AUA 2020, because of the growing need to find a valid alternative to BCG for patients with non-muscle invasive bladder cancer (NMIBC).
Read more
We take our time with you
We look forward to getting in touch with you
Thank you for your inquiry. We will answer you as soon as possible.
This site uses cookies to improve your user experience. You may find out more about in our Privacy Policy. By using this website you accept our use of cookies.
OK